在患有慢性肾脏疾病阶段的患者中,使用支持AI-AI-AI-ECG设备的高钾血症监测3-5 (POCKET)
在患有慢性肾脏疾病阶段的患者中,使用支持AI-AI-AI-ECG设备的高钾血症监测3-5的患者,以降低高钾血症的发生率
The clinical trial will be conducted in a real-world outpatients setting with the goal of learning if monitoring serum potassium frequently among patients with moderate-to-advanced stages of chronic kidney disease leading to optimal management of hyperkalemia (the reduced occurrence of serum potassium ≥ 5.0 mmol/L during 6 months of follow-up). It will also learn about the adherence of using a mobile monitoring device.
Participants will:
- Measure their serum potassium using an AI-enhanced point-of-care ECG device at least twice per week
- Receive health education prompts to reduce intake of potassium rich foods if their electrocardiogram device measured serum potassium is abnormal
- Receive alerts to visit nephrology clinic if their electrocardiogram device measured serum potassium is continuously abnormal
研究概览
地位
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Jinwei Wang, Ph.D.
- 电话号码:+86-010-83572388
- 邮箱:wangjinwei@bjmu.edu.cn
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100034
- 招聘中
- Peking University First Hospital
-
接触:
- Jinwei Wang, Ph.D.
- 电话号码:+86-010-83572388
- 邮箱:wangjinwei@bjmu.edu.cn
-
-
Guangxi
-
Nanning、Guangxi、中国、530021
- 尚未招聘
- The First Affiliated Hospital of Guangxi Medical University
-
接触:
- Ling Pan, M.D.
- 电话号码:+86-0771-5356533
- 邮箱:nnpanling008@sina.com
-
-
Hubei
-
Wuhan、Hubei、中国、430063
- 尚未招聘
- Hubei Provincial Hospital of TCM
-
接触:
- Xue Xue, M.D.
- 电话号码:+86-027-88710029
- 邮箱:2672754432@qq.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patients with chronic kidney disease stages 3b-5 (eGFR: 10 - <45 ml/min/1.73m²)
- Patients with regular visits in the study sites to manage their chronic kidney disease (≥ 1 visit per 3 months during the past year before enrollment)
- Willingness to participate in the study with signed informed consent
Exclusion Criteria:
- Patients already under kidney replacement therapy or will receive kidney replacement therapy in 6 months
- Unwillingness or without the ability to monitor hyperkalemia using the study device
- Patients with heart pacemaker implanted
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Monitoring plasma potassium using ECG device
Patients in this arm will use AI-enhanced point-of-care ECG device to monitor their serum potassium level every 3 days for 6 months in addition to their regular outpatients follow-up. If ECG device detected hyperkalemia was reported, more intensive monitoring, education on diet or offer of making outpatient appointment, as appropriate, will be provided. |
A mobile AI-enhanced electrocardiogram device will be used to help patients monitor hyperkalemia. The device, shaped like a stick of chewing gum, collects time-series data of electrocardiogram lead I through two electrodes. Deep convolutional neural network algorithm can read the data and generated categories of plasma potassium (<5 mmol/L, 5 - <5.5 mmol/L, 5.5 - <6.0 mmol/L and ≥ 6.0 mmol/L). Study participants receive the device after randomization. The staff establishes a WeChat group for each participant and reminds them to monitor plasma potassium every 3 days. When the detected plasma potassium category falls in 5 - <5.5 mmol/L, they will be reminded to watch diet and to verify plasma potassium again. More intensive reminding (once daily) will be sent if plasma potassium category falls in 5.5 - <6.0 mmol/L or ≥ 6.0 mmol/L. An extra outpatient appointment will also be made as soon as possible for the patients when their detected plasma potassium category is ≥ 6.0 mmol/L. |
|
无干预:Regular outpatients follow-up
Patients in this arm will just follow their regular outpatients care without additional intervention. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of serum potassium ≥ 5.0 mmol/L
大体时间:Six months (+1 month if outpatients visit delayed) after enrollment into the study
|
The serum potassium should be the laboratory measured one, which is obtained in the 3(±1) month and 6(±1) month follow-up in outpatients visit. |
Six months (+1 month if outpatients visit delayed) after enrollment into the study
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Average level of serum potassium
大体时间:Six month (+1 month if outpatients visit delayed) after enrollment into the study
|
The serum potassium should be the laboratory measured one, which is obtained in the 3(±1) month and 6(±1) month follow-up in outpatients visit. |
Six month (+1 month if outpatients visit delayed) after enrollment into the study
|
|
Frequency of using AI-enhanced ECG device to monitor serum potassium
大体时间:Six months (+1 month if outpatients visit delayed) after enrollment into the study and 3 months (+1 month if outpatients visit delayed) after the 6 months of intervention.
|
The frequency will be monitored in intervention period for the intervention group and after intervention (up to 4 months) for both the original intervention and control groups. |
Six months (+1 month if outpatients visit delayed) after enrollment into the study and 3 months (+1 month if outpatients visit delayed) after the 6 months of intervention.
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of serum potassium ≥ 5.0 mmol/L after the intervention period
大体时间:Three months (+1 month if outpatients visit delayed) after the 6 months of intervention
|
We collect incidence of serum potassium ≥ 5.0 mmol/L after the intervention period to see whether there is still a gap between the original intervention and control groups with the latter one having obtained the device. |
Three months (+1 month if outpatients visit delayed) after the 6 months of intervention
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 2024-943
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
IPD used in the results publication will be shared upon reasonable request.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.